A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score
- 1 May 2012
- journal article
- letter
- Published by Springer Science and Business Media LLC in Internal and Emergency Medicine
- Vol. 7 (3), 291-292
- https://doi.org/10.1007/s11739-012-0784-y
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT studyJournal of Translational Medicine, 2011
- Venous Thromboembolic DiseaseJournal of the National Comprehensive Cancer Network, 2011
- Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind studyThe Lancet Oncology, 2009
- Development and validation of a predictive model for chemotherapy-associated thrombosisBlood, 2008
- Venous thromboembolism and cancer: a two-way clinical association.1997
- Venous Thromboembolism and Gancer: a Two-Way Clinical AssociationThrombosis and Haemostasis, 1997